Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. Issue 2 (22nd April 2022)

• Record Type: Journal Article
• Authors: Jessen, Frank; Wolfsgruber, Steffen; Kleineindam, Luca; Spottke, Annika; Altenstein, Slawek; Bartels, Claudia; Berger, Moritz; Brosseron, Frederic; Daamen, Marcel; Dichgans, Martin; Dobisch, Laura; Ewers, Michael; Fenski, Friederike; Fliessbach, Klaus; Freiesleben, Silka D.; Glanz, Wenzel; Görß, Doreen; Gürsel, Selim; Janowitz, Daniel; Kilimann, Ingo; Kobeleva, Xenia; Lohse, Andrea; Maier, Franziska; Metzger, Coraline; Munk, Matthias; Preis, Lukas; Sanzenbacher, Carolin; Spruth, Eike; Rauchmann, Boris; Vukovich, Ruth; Yakupov, Renat; Weyrauch, Anne‐Sophie; Ziegler, Gabriel; Schmid, Matthias; Laske, Christoph; Perneczky, Robert; Schneider, Anja; Wiltfang, Jens; Teipel, Stefan; Bürger, Katharina; Priller, Josef; Peters, Oliver; Ramirez, Alfredo; Boecker, Henning; Heneka, Michael T.; Wagner, Michael; Düzel, Emrah;
• Is Part Of: Alzheimer's & dementia. Volume 19:Issue 2(2023)
• Page Start: 487
• Page End: 497
• Publication Date: 2022-04-22
• Subjects: amyloid beta 42 -- Alzheimer's disease -- apolipoprotein E -- cerebrospinal fluid -- longitudinal -- magnetic resonance imaging -- mild cognitive impairment -- positron emission tomography -- subjective cognitive decline -- tau; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.12674
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: It is uncertain whether subjective cognitive decline (SCD) in individuals who seek medical help serves the identification of the initial symptomatic stage 2 of the Alzheimer's disease (AD) continuum. Methods: Cross‐sectional and longitudinal data from the multicenter, memory clinic–based DELCODE study. Results: The SCD group showed slightly worse cognition as well as more subtle functional and behavioral symptoms than the control group (CO). SCD–A+ cases (39.3% of all SCD) showed greater hippocampal atrophy, lower cognitive and functional performance, and more behavioral symptoms than CO–A+. Amyloid concentration in the CSF had a greater effect on longitudinal cognitive decline in SCD than in the CO group. Discussion: Our data suggests that SCD serves the identification of stage 2 of the AD continuum and that stage 2, operationalized as SCD‐A+, is associated with subtle, but extended impact of AD pathology in terms of neurodegeneration, symptoms and clinical progression.